Products
Bring a target,a candidate, or capital.
Design and rank candidates in EPiQ, de-risk one you already have with PharmPhax, or back the four programs and the models that designed them.
Six products.
Three audiences
De-risk
PharmPhax™
PharmPhax is an industrial-grade translational de-risking report for existing radiopharmaceutical candidates.
Invest
Therapeutic Pipeline
Epitorix runs its own AI-designed radiopharmaceutical programs, from computational design through in vitro binding into in vivo validation.
Invest
Epitorix AI models
The proprietary models, datasets and compute underneath everything Epitorix ships.
How the six products fit together
Build
De-risk
Invest
Xenoclea is built into EPiQ. PharmacoLaw includes PharmPhax. The Therapeutic Pipeline is designed with the Epitorix AI models.
De-risk
Translational de-risking reports for radiopharmaceutical candidates.
Translational de-risking is testing a candidate for the liabilities that end programs — off-target binding, biodistribution, organ and cell-type exposure, PK and PD — before trials begin, so failures happen on paper instead. Bring an existing radiopharmaceutical candidate: Epitorix AI models, with expert scientific review, identify its likely causes of failure, and PharmacoLaw adds the patent, regulatory and legal exposure.
How the models predict organ riskBiodistribution and dosimetry, explained
Translational de-risking report
PharmPhax
PharmPhax is an industrial-grade translational de-risking report for existing radiopharmaceutical candidates. Epitorix AI models, with expert scientific review, analyze off-target interactions, biodistribution, organ exposure, cell-type risk, PK and PD to identify likely causes of failure before clinical trials begin.
- Bring an existing candidate
- AI analysis plus expert scientific review
- Up to 93% accuracy, retrospective analyses
In retrospective analyses of radiopharmaceuticals with documented clinical outcomes, our models detected previously reported development and safety liabilities with up to 93% accuracy.
Legal & regulatory exposure
PharmacoLaw
PharmacoLaw reads biology and law in one report: biological and clinical risk together with patent, regulatory and legal exposure, so investigators and investors see the whole liability picture before committing capital. Everything in PharmPhax is included.
- Includes PharmPhax in full
- Patent, regulatory and legal exposure
- For current or developing drugs
Contact
Bring us a target.
A target to design against, a candidate to de-risk, or the pipeline data.
Laboratory bench · liquid handler and assay plates